Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CEMPRA, INC. (MLNT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/24/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 06/12/2020 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 04/20/2020 |
S-3DPOS
| Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective: |
| 04/20/2020 |
S-3DPOS
| Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective: |
| 04/20/2020 |
S-3DPOS
| Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective: |
| 04/20/2020 |
S-3DPOS
| Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective: |
| 04/20/2020 |
S-3DPOS
| Form S-3DPOS - Post-effective amendments, registration of securities, dividend or interest reinvestment plans, immediately effective: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/20/2020 |
8-K
| Bankruptcy or Receivership, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Ch... |
| 04/14/2020 |
8-K
| Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/14/2020 |
8-K
| Quarterly results |
| 02/05/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/08/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 12/27/2019 |
8-K
| Quarterly results |
| 11/12/2019 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 11/06/2019 |
8-K
| Other Events |
| 10/25/2019 |
3
| Lococo Ryan (COO) has filed a Form 3 on MELINTA THERAPEUTICS, INC. /NEW/ |
| 10/25/2019 |
3
| Blum Susan (VP of Finance & CAO) has filed a Form 3 on MELINTA THERAPEUTICS, INC. /NEW/ |
| 10/24/2019 |
8-K
| Quarterly results |
| 09/13/2019 |
3
| Sanfilippo Jennifer A (interim Chief Executive Office) has filed a Form 3 on MELINTA THERAPEUTICS, INC. /NEW/ |
| 09/03/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"FORM 8-K",
"Separation and Release Agreement, between Melinta Therapeutics, Inc. and John H. Johnson",
"Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director MORRISTOWN, N.J., September 3, 2019 - Melinta Therapeutics, Inc. , a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer's appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors. Jennifer is also an ideal addition to Melinta's board of directors and we are pleased that th..." |
|
| 08/12/2019 |
SC 13D/A
| Vatera Healthcare Partners LLC reports a 55.1% stake in Melinta Therapeutics, Inc. |
| 08/09/2019 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
| 08/09/2019 |
8-K
| Quarterly results |
| 07/16/2019 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 07/10/2019 |
SC 13G/A
| FMR LLC reports a 0% stake in MELINTA THERAPEUTICS INC |
|
|
|